147 related articles for article (PubMed ID: 2527549)
1. Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.
Anderson ED; Forrest AP; Levack PA; Chetty U; Hawkins RA
Br J Cancer; 1989 Aug; 60(2):223-6. PubMed ID: 2527549
[TBL] [Abstract][Full Text] [Related]
2. Primary systemic therapy for operable breast cancer.
Anderson ED; Forrest AP; Hawkins RA; Anderson TJ; Leonard RC; Chetty U
Br J Cancer; 1991 Apr; 63(4):561-6. PubMed ID: 1827031
[TBL] [Abstract][Full Text] [Related]
3. Endocrine and clinical aspects of new compounds for treatment of hormone-related cancer in gynecology.
von Matthiessen H; Distler W
Recent Results Cancer Res; 1990; 118():190-5. PubMed ID: 2146725
[No Abstract] [Full Text] [Related]
4. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients.
Lien EA; Johannessen DC; Aakvaag A; Lønning PE
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):541-3. PubMed ID: 1532904
[TBL] [Abstract][Full Text] [Related]
5. New trends in the endocrine treatment of breast cancer.
Maass H; Jonat W; Eidtmann H; Kunz T; Kügler G
Recent Results Cancer Res; 1990; 118():225-32. PubMed ID: 2146726
[No Abstract] [Full Text] [Related]
6. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
[TBL] [Abstract][Full Text] [Related]
7. Oestrogen receptors and the response of metastatic breast cancer to aminoglutethimide or tamoxifen.
Holdaway IM
Aust N Z J Surg; 1981 Aug; 51(4):345-7. PubMed ID: 6944051
[TBL] [Abstract][Full Text] [Related]
8. Does the oestrogen receptor concentration of a breast cancer change during systemic therapy?
Hawkins RA; Tesdale AL; Anderson ED; Levack PA; Chetty U; Forrest AP
Br J Cancer; 1990 Jun; 61(6):877-80. PubMed ID: 2372489
[TBL] [Abstract][Full Text] [Related]
9. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.
Dowsett M; Stein RC; Coombes RC
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):155-9. PubMed ID: 1388047
[TBL] [Abstract][Full Text] [Related]
10. Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation.
Nicholson RI; Bouzubar N; Walker KJ; McClelland R; Dixon AR; Robertson JF; Ellis IO; Blamey RW
Eur J Cancer; 1991; 27(7):908-13. PubMed ID: 1834127
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer.
Robertson JF; Bates K; Pearson D; Blamey RW; Nicholson RI
Br J Cancer; 1992 May; 65(5):727-30. PubMed ID: 1534019
[TBL] [Abstract][Full Text] [Related]
12. Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer.
Gazet JC; Coombes RC; Ford HT; Griffin M; Corbishley C; Makinde V; Lowndes S; Quilliam J; Sutcliffe R
Br J Cancer; 1996 Mar; 73(6):758-62. PubMed ID: 8611376
[TBL] [Abstract][Full Text] [Related]
13. Randomised trial of chemotherapy versus endocrine therapy in patients presenting with locally advanced breast cancer (a pilot study).
Gazet JC; Ford HT; Coombes RC
Br J Cancer; 1991 Feb; 63(2):279-82. PubMed ID: 1825469
[TBL] [Abstract][Full Text] [Related]
14. Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
Dixon AR; Robertson JF; Jackson L; Nicholson RI; Walker KJ; Blamey RW
Br J Cancer; 1990 Nov; 62(5):868-70. PubMed ID: 2147110
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer.
Nicholson S; Halcrow P; Sainsbury JR; Angus B; Chambers P; Farndon JR; Harris AL
Br J Cancer; 1988 Dec; 58(6):810-4. PubMed ID: 3224082
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values.
Rose C; Thorpe SM; Andersen KW; Pedersen BV; Mouridsen HT; Blichert-Toft M; Rasmussen BB
Lancet; 1985 Jan; 1(8419):16-9. PubMed ID: 2856949
[TBL] [Abstract][Full Text] [Related]
17. Quantitative oestrogen and progesterone receptor values in primary breast cancer and predictability of response to endocrine therapy.
Fernandez MD; Alaghband-Zadeh J; Burn JI
Clin Oncol; 1983 Sep; 9(3):245-50. PubMed ID: 6616999
[TBL] [Abstract][Full Text] [Related]
18. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer.
Nicholson S; Sainsbury JR; Halcrow P; Chambers P; Farndon JR; Harris AL
Lancet; 1989 Jan; 1(8631):182-5. PubMed ID: 2463445
[TBL] [Abstract][Full Text] [Related]
19. Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy.
Henry JA; Nicholson S; Hennessy C; Lennard TW; May FE; Westley BR
Br J Cancer; 1990 Jan; 61(1):32-8. PubMed ID: 2153395
[TBL] [Abstract][Full Text] [Related]
20. Steroid-hormone receptors in breast cancer.
Wittliff JL
Cancer; 1984 Feb; 53(3 Suppl):630-43. PubMed ID: 6692266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
